AMPLIFY-201: ELI-002 2P Vaccine for Pancreatic and Colorectal Cancer
By Shubham Pant, MD, MBBS - Last Updated: March 19, 2025Shubham Pant, MD, MBBS, of the MD Anderson Cancer Center, highlights the phase 1 AMPLIFY-201 trial and the potential impact of the ELI-002 2P vaccine for patients with pancreatic and colorectal cancer.
Advertisement
Dr. Pant discusses the relationship between T cell response magnitude and tumor biomarker reduction and how this research may change the treatment landscape for patients with KRAS-mutated pancreatic and colorectal cancers.
Advertisement
Related Posts
Dr. El-Rayes reflects on his career in translational research, emphasizing his efforts to expand trial infrastructure.
Dr. Cleary discusses DDR deficiencies in metastatic pancreatic cancer and reviews the use of PARP inhibitors.
Zenocutuzumab may serve as an effective treatment for NRG1 fusion-positive pancreatic cancer, with low-grade AEs.
Drs. Stephen Liu and Benjamin Weinberg continue their discussion on the safety of zenocutuzumab in NRG1 fusion+ PDAC.
Drs. Stephen Liu and Benjamin Weinberg elaborate on the prevalence of NRG1 gene fusions in PDAC.
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.